Literature DB >> 23211868

Halting metastasis through CXCR4 inhibition.

Deborah M Ramsey1, Shelli R McAlpine.   

Abstract

Metastasis occurs when cancer cells leave the primary tumor site and migrate to distant parts of the body. The CXCR4-SDF-1 pathway facilitates this migration, and its expression has become the hallmark of several metastatic cancers. Targeted approaches are currently being developed to inhibit this pathway, and several candidates are now in clinical trials. Continued exploration of CXCR4 inhibitors will generate compounds that have improved activity over current candidates.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23211868     DOI： 10.1016/j.bmcl.2012.10.138

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  28 in total

1.  Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer.

Authors:  T L Mao; K F Fan; C L Liu
Journal:  Gene Ther       Date:  2017-09-07       Impact factor: 5.250

2.  Expression of the CXCL12/CXCR4 chemokine axis predicts regional control in head and neck squamous cell carcinoma.

Authors:  Xavier León; Santiago Diez; Jacinto García; Joan Lop; Anna Sumarroca; Miquel Quer; Mercedes Camacho
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-06-21       Impact factor: 2.503

3.  Prognostic value of CXCL12 and CXCR4 in inoperable head and neck squamous cell carcinoma.

Authors:  Margret Rave-Fränk; Narges Tehrany; Julia Kitz; Martin Leu; Hanne Elisabeth Weber; Peter Burfeind; Henning Schliephake; Martin Canis; Tim Beissbarth; Holger Michael Reichardt; Hendrik Andreas Wolff
Journal:  Strahlenther Onkol       Date:  2015-09-15       Impact factor: 3.621

4.  Subsets of cancer cells expressing CX3CR1 are endowed with metastasis-initiating properties and resistance to chemotherapy.

Authors:  Ramanpreet Kaur; Chen Qian; Anthony DiNatale; Jieyi Zhang; Michael Marchioli; Darin Ipe; Maria Castelli; Chris M McNair; Gaurav Kumar; Olimpia Meucci; Alessandro Fatatis
Journal:  Oncogene       Date:  2022-01-08       Impact factor: 8.756

Review 5.  Pancreatic cancer stem cell markers and exosomes - the incentive push.

Authors:  Sarah Heiler; Zhe Wang; Margot Zöller
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

Review 6.  Unravelling cancer stem cell potential.

Authors:  Benjamin Beck; Cédric Blanpain
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

7.  IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis.

Authors:  Janani Panneerselvam; Jiankang Jin; Manish Shanker; Jason Lauderdale; Jonathan Bates; Qi Wang; Yan D Zhao; Stephen J Archibald; Timothy J Hubin; Rajagopal Ramesh
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

Review 8.  Emerging targets in cancer management: role of the CXCL12/CXCR4 axis.

Authors:  Monica Cojoc; Claudia Peitzsch; Franziska Trautmann; Leo Polishchuk; Gennady D Telegeev; Anna Dubrovska
Journal:  Onco Targets Ther       Date:  2013-09-30       Impact factor: 4.147

Review 9.  At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer.

Authors:  Gary D Luker; Jinming Yang; Ann Richmond; Stefania Scala; Claudio Festuccia; Margret Schottelius; Hans-Jürgen Wester; Johann Zimmermann
Journal:  J Leukoc Biol       Date:  2020-10-26       Impact factor: 4.962

10.  CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors.

Authors:  Ruchi Saxena; Yan Wang; James W Mier
Journal:  Melanoma Res       Date:  2020-02       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.